secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cytek Biosciences, Inc. (CTKB)
CIK:        0001831915
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001193125-25-174459
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cytek Q2 2025 revenue $45.6M (-2% YoY); narrows 2025 guidance to $196-205M
--------------------------------------------------------------------------

- Revenue $45.6M, down 2% YoY; net loss $5.6M vs $10.4M loss in Q2 2024.
- Adjusted EBITDA $1.3M (down from $2.9M); operating loss $10.6M vs $8.5M.
- Installed base grew to 3,295 instruments (146 new units); launched Aurora Evo system.
- Recurring revenue up 16% YoY; repurchased $4.5M in stock during Q2.
- 2025 revenue guidance narrowed to $196-205M (flat to -2% growth over 2024).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831915/000119312525174459/0001193125-25-174459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831915/000119312525174459/d27070d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-174459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer